{"anticipatedPostingDate":"2026-10","denomUnitsSelected":"Participants","description":"ORR: % of participants with objective response. stringent complete response (sCR):CR; ii) normal serum free light chain (FLC) ratio; absence of clonal cells in bone marrow biopsy (BMB)/ bone marrow aspirate (BMA) by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was normal serum FLC ratio of 0.26-1.65. VGPR:Serum and urine M-protein detectable by immunofixation but not on electrophoresis;\\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 h; if only measurable disease is by serum FLC levels, VGPR:\\>=90% decrease in difference between involved and uninvolved serum FLC levels; in addition if present at baseline, \\>90% reduction compared to baseline in size of soft tissue plasmacytomas. PR:≥50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by ≥90% or to \\<200 mg/24 h.","reportingStatus":"NOT_POSTED","timeFrame":"Parts 1 and 2: From start of treatment to end of the study (approximately 3 years 7 months)","title":"Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria as Determined by Investigator: Parts 1 and 2","type":"SECONDARY"}